Caplin Steriles, Xellia Pharma ink distribution pact for 5 injectables in US
"Caplin Steriles Limited (a Subsidiary of Caplin Point Laboratories Ltd) has entered into a private label distribution agreement with Xellia Pharmaceuticals for five generic injectable abbreviated new drug application (ANDA) in the US," it said.;
Advertisement
New Delhi: Drug firm Caplin Point Laboratories on Tuesday said its subsidiary has entered into a distribution agreement with Xellia Pharmaceuticals for five injectable products in the US.
The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin Point Laboratories said in a BSE filing.
"Caplin Steriles Limited (a Subsidiary of Caplin Point Laboratories Ltd) has entered into a private label distribution agreement with Xellia Pharmaceuticals for five generic injectable abbreviated new drug application (ANDA) in the US," it said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.